Outlook Therapeutics Hits 52-Week Low As It Launches Proposed Public Offering

Outlook Therapeutics announced a proposed best-efforts public offering of common stock and accompanying warrants while its shares trade at a fresh 52-week low. The issuance should provide near-term liquidity but is dilutive and likely to increase downward pressure and volatility on the equity, raising investor risk in the near term.

Analysis

Outlook Therapeutics announced a proposed best-efforts public offering of common stock and accompanying warrants while its shares trade at a fresh 52-week low. The issuance should provide near-term liquidity but is dilutive and likely to increase downward pressure and volatility on the equity, raising investor risk in the near term.